QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
EMC Corp stock logo
EMC
EMC
$25.03
-0.5%
$0.00
$22.99
$29.13
N/AN/A13.90 million shs74,442 shs
PAR Technology Co. stock logo
PAR
PAR Technology
$40.09
0.0%
$43.97
$24.76
$49.84
$1.36B1.98237,073 shs287,366 shs
Pfenex Inc. stock logo
PFNX
Pfenex
$12.75
$0.00
$5.26
$14.00
$437.29MN/A503,865 shsN/A
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
EMC Corp stock logo
EMC
EMC
+0.00%-4.95%-1.79%+1.79%-13.42%
PAR Technology Co. stock logo
PAR
PAR Technology
-1.64%-9.27%-2.03%-10.21%+24.72%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
EMC Corp stock logo
EMC
EMC
0.536 of 5 stars
0.04.01.70.00.01.70.7
PAR Technology Co. stock logo
PAR
PAR Technology
0.3397 of 5 stars
2.40.00.00.02.00.80.6
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
EMC Corp stock logo
EMC
EMC
N/AN/AN/AN/A
PAR Technology Co. stock logo
PAR
PAR Technology
2.71
Moderate Buy$48.5721.16% Upside
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/A

Current Analyst Ratings

Latest EMC, PAR, and PFNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/28/2024
PAR Technology Co. stock logo
PAR
PAR Technology
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$53.00
3/12/2024
PAR Technology Co. stock logo
PAR
PAR Technology
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/12/2024
PAR Technology Co. stock logo
PAR
PAR Technology
Sidoti
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$61.00
2/27/2024
PAR Technology Co. stock logo
PAR
PAR Technology
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$47.00 ➝ $53.00
2/13/2024
PAR Technology Co. stock logo
PAR
PAR Technology
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold
1/29/2024
PAR Technology Co. stock logo
PAR
PAR Technology
Sidoti
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
EMC Corp stock logo
EMC
EMC
N/AN/AN/AN/AN/AN/A
PAR Technology Co. stock logo
PAR
PAR Technology
$415.82M3.27N/AN/A$11.89 per share3.37
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
EMC Corp stock logo
EMC
EMC
N/A$2.0512.21N/AN/AN/AN/AN/A
PAR Technology Co. stock logo
PAR
PAR Technology
-$69.75M-$2.53N/AN/AN/A-16.77%-16.46%-6.90%5/8/2024 (Estimated)
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/A0.00N/AN/AN/AN/AN/A

Latest EMC, PAR, and PFNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/27/2024Q4 2023
PAR Technology Co. stock logo
PAR
PAR Technology
-$0.42-$0.47-$0.05-$0.27$106.12 million$107.71 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
EMC Corp stock logo
EMC
EMC
$0.461.84%N/A22.44%N/A
PAR Technology Co. stock logo
PAR
PAR Technology
$0.310.77%N/AN/A N/A
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
EMC Corp stock logo
EMC
EMC
N/AN/AN/A
PAR Technology Co. stock logo
PAR
PAR Technology
1.13
2.25
1.96
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
EMC Corp stock logo
EMC
EMC
79.86%
PAR Technology Co. stock logo
PAR
PAR Technology
N/A
Pfenex Inc. stock logo
PFNX
Pfenex
N/A

Insider Ownership

CompanyInsider Ownership
EMC Corp stock logo
EMC
EMC
0.40%
PAR Technology Co. stock logo
PAR
PAR Technology
3.67%
Pfenex Inc. stock logo
PFNX
Pfenex
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
EMC Corp stock logo
EMC
EMC
N/AN/AN/ANot Optionable
PAR Technology Co. stock logo
PAR
PAR Technology
1,84133.95 million32.70 millionOptionable
Pfenex Inc. stock logo
PFNX
Pfenex
7134.30 millionN/ANot Optionable

EMC, PAR, and PFNX Headlines

SourceHeadline
NKY Medical Holdings Ltd Class A 300109NKY Medical Holdings Ltd Class A 300109
morningstar.com - January 31 at 6:39 PM
Last available seats at PFS West Coast Conference next weekLast available seats at PFS West Coast Conference next week
pharmaphorum.com - May 19 at 6:04 PM
Ligand Pharmaceuticals and Playa Hotels Resorts Exceed Q1 ... - Best StocksLigand Pharmaceuticals and Playa Hotels Resorts Exceed Q1 ... - Best Stocks
news.google.com - May 4 at 7:30 PM
150+ Active Companies working to develop 160+ Pipeline ... - Digital Journal150+ Active Companies working to develop 160+ Pipeline ... - Digital Journal
news.google.com - April 13 at 12:19 AM
Heres Why You Should Add Ligand (LGND) Stock to Your Portfolio - NasdaqHere's Why You Should Add Ligand (LGND) Stock to Your Portfolio - Nasdaq
news.google.com - April 6 at 5:35 PM
LENZ Therapeutics Closes $83.5M Series B - San Diego Business JournalLENZ Therapeutics Closes $83.5M Series B - San Diego Business Journal
news.google.com - March 29 at 1:06 PM
Ranibizumab Biosimilars Report 2023: Therapies and Ranibizumab ... - Digital JournalRanibizumab Biosimilars Report 2023: Therapies and Ranibizumab ... - Digital Journal
news.google.com - March 17 at 10:21 AM
Global Inflammatory Bowel Disease (IBD) Therapeutics Market to ... - GlobeNewswireGlobal Inflammatory Bowel Disease (IBD) Therapeutics Market to ... - GlobeNewswire
news.google.com - March 15 at 8:24 PM
San Diegos Lenz Therapeutics snags $83.5M for once-a-day eye ... - The San Diego Union-TribuneSan Diego's Lenz Therapeutics snags $83.5M for once-a-day eye ... - The San Diego Union-Tribune
news.google.com - March 15 at 8:24 PM
Osteoporosis Treatment research scope: In-depth Growth Analysis ... - Digital JournalOsteoporosis Treatment research scope: In-depth Growth Analysis ... - Digital Journal
news.google.com - March 13 at 7:40 AM
Current and Future Analysis of Osteoporosis Treatment Market With New Business Strategies and Forecast by 2030 - openPRCurrent and Future Analysis of Osteoporosis Treatment Market With New Business Strategies and Forecast by 2030 - openPR
news.google.com - March 1 at 11:39 AM
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results - The Bakersfield CalifornianLigand Reports Fourth Quarter and Full Year 2022 Financial Results - The Bakersfield Californian
news.google.com - February 23 at 5:24 PM
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results - Business WireLigand Reports Fourth Quarter and Full Year 2022 Financial Results - Business Wire
news.google.com - February 22 at 5:46 PM
Biosimilar Growth Hormones Global Market Report 2023 - Yahoo FinanceBiosimilar Growth Hormones Global Market Report 2023 - Yahoo Finance
news.google.com - February 8 at 4:13 PM
Biosimilar Therapeutic Peptides Global Market Report 2023 - Yahoo FinanceBiosimilar Therapeutic Peptides Global Market Report 2023 - Yahoo Finance
news.google.com - February 8 at 4:13 PM
Osteoporosis Treatment Market Set to Witness Explosive Growth By ... - Digital JournalOsteoporosis Treatment Market Set to Witness Explosive Growth By ... - Digital Journal
news.google.com - February 7 at 3:49 AM
Injectable Drug Delivery Market Dynamic Demand, Growth ... - PharmiWeb.comInjectable Drug Delivery Market Dynamic Demand, Growth ... - PharmiWeb.com
news.google.com - January 27 at 9:00 PM
Osteoporosis Treatment Market Research Scope: In-Depth Growth ... - Digital JournalOsteoporosis Treatment Market Research Scope: In-Depth Growth ... - Digital Journal
news.google.com - January 27 at 9:34 AM
Injectable Drug Delivery Market 2023 Segmentation and Regional Analysis by 2032 - openPRInjectable Drug Delivery Market 2023 Segmentation and Regional Analysis by 2032 - openPR
news.google.com - January 6 at 1:28 PM
Abzena Names Matthew Stober CEO - Contract PharmaAbzena Names Matthew Stober CEO - Contract Pharma
news.google.com - January 5 at 2:36 PM
Abzena hires Matthew Stober to lead the company through the next ... - Bio-IT WorldAbzena hires Matthew Stober to lead the company through the next ... - Bio-IT World
news.google.com - January 4 at 5:54 PM
Osteoporosis Treatment Market Will Reflect Significant Growth Prospects during 2022 – 2028 | Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED. - Digital JournalOsteoporosis Treatment Market Will Reflect Significant Growth Prospects during 2022 – 2028 | Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED. - Digital Journal
news.google.com - December 7 at 8:29 AM
Ligand Reports Third Quarter 2022 Financial Results - StreetInsider.comLigand Reports Third Quarter 2022 Financial Results - StreetInsider.com
news.google.com - November 8 at 4:47 AM
Krystal Biotech Stock: A Buy For Growth Potential (NASDAQ:KRYS) - Seeking AlphaKrystal Biotech Stock: A Buy For Growth Potential (NASDAQ:KRYS) - Seeking Alpha
news.google.com - November 6 at 2:43 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

EMC logo

EMC

NYSE:EMC
EMC Corporation (EMC) develops, delivers and supports the information technology (IT) industry's range of information infrastructure and virtual infrastructure technologies, solutions and services. EMC manages the Company as part of a federation of businesses: EMC Information Infrastructure, VMware Virtual Infrastructure, Pivotal and Virtustream. EMC's Information Infrastructure business provides a foundation for organizations to store, manage, protect, analyze and secure information. EMC's VMware Virtual Infrastructure business is engaged in virtualization and cloud infrastructure solutions that enable businesses to help transform the way they build, deliver and consume IT resources in a manner that is based on their specific needs. EMC's Pivotal business unites strategic technology, people and programs from EMC and VMware and has a platform that consists of data, agile development practices and a cloud independent platform-as-a-service.
PAR Technology logo

PAR Technology

NYSE:PAR
PAR Technology Corporation, together with its subsidiaries, provides omnichannel cloud-based hardware and software solutions to the restaurant and retail industries worldwide. The Restaurant/Retail segment offers PUNCHH, an enterprise-grade customer loyalty and engagement solution; MENU, an eCommerce platform for restaurant brands; BRINK POS, an open cloud, point-of-sale solution; PAR PAYMENT SERVICES, a merchant services business that enables electronic payment and processing services for businesses; and DATA CENTRAL, a back-office solution that leverages business intelligence and automation technologies. This segment also offers Point-of-Sale Hardware; wireless headsets for drive-thru order-taking; and kitchen display systems, payment devices, cash drawers, printers, and other peripherals. In addition, this segment provides services, such as hardware repair, installation and implementation, training, and on-site and technical support services. The Government segment provides intelligence, surveillance, and reconnaissance solutions; mission systems operations and maintenance, and commercial software products; systems engineering support and software-based solutions; satellite and teleport facility operation and maintenance, engineering, and installation services comprising inside and outside plant services, and maintenance of infrastructure and information systems; satellite ground system support comprising operations and maintenance, sustainment, upgrades, communications security management, anomaly response/resolution, process improvement, emergency response, and disaster recovery services; and information technology infrastructure library services to the United States Department of Defense, intelligence community (IC), and other federal agencies. This segment also offers various IC support services, systems integration, situational awareness solutions, and mission readiness support services. The company was founded in 1968 and is based in New Hartford, New York.
Pfenex logo

Pfenex

NYSEAMERICAN:PFNX
Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.